Tags OTCQB
Tag: OTCQB
Vivos Inc.'s IsoPet® cancer therapy reports record Q1 2025 growth with 150% more treatments, new clinic certifications, and expanded therapeutic applications.
Vivos Inc. reports major progress in its India human trial for RadioGel®, showing high safety and localized tumor treatment precision.
Vivos Inc. Expands IsoPet® Animal Cancer Division in 2025
Vivos Inc. (OTCQB: RDGL) strengthens its IsoPet® division in 2025 with the expansion of clinics, training...
Vivos Inc. advances cancer treatment with RadioGel® PRnT™ Human trials in India show early success, with Mayo Clinic expansion planned in 2025.
Vivos Inc. converts IDE submission to Pre-Sub filing with FDA approval, focusing on comprehensive review and risk/benefit analysis for Radiogel®
IsoPet® by Vivos Inc. (OTCQB: RDGL) uses Yttrium-90 for precise cancer treatment in animals. Learn about its technology, clinic expansion, and future plans.
Vivos Inc. advances with Reg A-1 filing to support human trials and expand animal therapies, reflecting growth potential and commitment to oncology innovation.
Vivos Inc. (RDGL) announces submission of IDE application to FDA for RadioGel™, advancing treatment for papillary thyroid cancer.
Explore TraderQue's Week 20 OTC Watchlist for the latest market trends, top-performing stocks, and emerging investment opportunities in the OTC markets.
Our goal is to highlight stocks that might not be on every investor's radar but show potential for growth or interesting activity.
